Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
Medical Devices & Diagnostics
Pharma & Biotech
Medical Devices & Diagnostics
Why Abbott’s Ultreon 3.0 could reshape stent planning in complex coronary disease
AI can now guide coronary imaging in real time. Abbott’s Ultreon 3.0 puts precision PCI closer to routine clinical workflow.
Pharma & Biotech
From ARPA-H to Basilea: What Phare Bio’s new deal reveals about biotech partnerships
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.
Pharma & Biotech
Lilly’s $40m commitment to IU aims to transform Alzheimer’s research and trials
Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.